Immunic Stock
Immunic, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Erik Lundgren
- Employees
- 100
- Market cap
- $95 M
- IPO
- 17/04/2014
- Web
- imux.com
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting…
Immunic stock: price history
1D
-1.8%
1W
-14.9%
1M
-31.1%
6M
-30.3%
YTD
+30.5%
1Y
-14.6%
2Y
-54.7%
5Y
-92.0%
10Y
-99.7%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~36% weaker price swings than usual
Ask the agents about Immunic
Analyst assessment of Immunic
PRICE TARGET LOW
US$19.00
CONSENSUS
US$28.67
MEDIAN
US$22.00
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 10/09/2026
Immunic stock metrics
P/E
-1.45
P/B
2.32
EV/EBITDA
0.53
RETURN ON EQUITY
-26.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.0%
FLOAT SHARES
12,006,312
AVG. DAILY VOLUME (30D)
428,432
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Immunic stock
What does Immunic do?
Immunic, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Erik Lundgren, the company employs around 100 people.
The IPO was on 17/04/2014; the stock trades on NASDAQ under the ticker IMUX.
What do analysts say about Immunic stock?
12 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$28.67, ranging from US$19.00 to US$45.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does Immunic report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -36% stronger than usual.
Does Immunic pay a dividend?
No, Immunic currently does not pay a dividend.
Which stocks are comparable to Immunic?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Immunic stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immunic against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.